サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1414661

ワクチンアジュバントの世界市場レポート 2024年

Vaccine Adjuvants Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ワクチンアジュバントの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

ワクチンアジュバントの市場規模は近年力強く成長しています。2023年の17億7,000万米ドルから2024年には19億1,000万米ドルに、CAGR8.0％で拡大します。この成長は、ワクチン開発の増加、感染症の流行、政府の取り組み、予防接種プログラム、研究開発への多額の投資、ワクチン流通の世界化に起因しています。

ワクチンアジュバント市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR8.2％で26億2,000万米ドルに成長します。予測期間中に予想される成長は、パンデミックへの備え、ワクチンポートフォリオの多様化、予防接種に関する世界の目標、共同研究やパートナーシップ、治療用ワクチンの重視などに関連しています。予測期間中に予想される顕著な動向には、アジュバント技術の進歩、免疫原性の強化への注力、効果を高めるためのアジュバントの併用、より安全で忍容性の高いアジュバントへの需要、個別化ワクチンやアジュバントの開発などが含まれます。

ワクチンアジュバント市場の予想される成長は、感染症の有病率の増加によって牽引されると予想されます。感染症には、ウイルス、細菌、真菌、寄生虫によって引き起こされる感染症が含まれます。ワクチンは、B型肝炎（HBV）、C型肝炎（HCV）、HIV、マラリア、梅毒、ブルセラ病など、さまざまな感染症の治療に重要な役割を果たしています。2022年の世界保健機関（WHO）の報告によると、2021年には世界で約1,060万人が結核に感染し、160万人が死亡、150万人がHIVに感染し、65万人が命を落としました。したがって、感染症の流行の高まりは、ワクチンアジュバント市場の主要な促進要因になると予想されます。

ワクチンアジュバント市場の成長は、ワクチン研究活動への資金提供の増加によっても促進されると予想されます。ワクチン研究活動は、感染症を予防するワクチンの開発、試験、強化に焦点を当てた包括的な科学的努力を包含しています。これらの調査活動は、天然物、合成化合物、さらには細菌やウイルスなど、多様な供給源に由来する潜在的なアジュバント候補の特定、試験、最適化において重要な役割を果たしています。例えば、2023年10月、米国を拠点とする重要な福祉サービスを提供する米国保健社会福祉省は、次世代ワクチン接種・治療プラットフォームのための第2b相臨床試験計画と最先端技術の開発を開始するための5億米ドルの投資を含むプロジェクトNextGenを発表しました。その結果、ワクチン研究活動への資金提供の増加が、ワクチンアジュバント市場成長の原動力となっています。

2023年のワクチンアジュバント市場で最大の地域は北米でした。アジア太平洋は、予測期間中にワクチンアジュバント世界市場レポートにおいて最も急成長する地域となる見込みです。ワクチンアジュバント市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のワクチンアジュバント市場、製品タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • アジュバントエマルジョン
  • 病原体の成分
  • 粒子状アジュバント
  • 併用アジュバント
  • その他の製品タイプ
  • 世界のワクチンアジュバント市場、適用経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ヒトワクチンアジュバント
  • 獣医用ワクチンアジュバント
  • 世界のワクチンアジュバント市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 筋肉内
  • 鼻腔内
  • 皮下
  • 皮内
  • 世界のワクチンアジュバント市場、疾患別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • がん
  • 感染症
  • その他の疾患

第7章 地域および国の分析

  • 世界のワクチンアジュバント市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のワクチンアジュバント市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ワクチンアジュバント市場の競合情勢
  • ワクチンアジュバント市場の企業プロファイル
    • GlaxoSmithKline Plc.
    • Novavax Inc.
    • SPI Pharma Inc.
    • Agenus Inc.
    • CSL Limited

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r12171

“Vaccine Adjuvants Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vaccine adjuvants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vaccine adjuvants? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The vaccine adjuvants market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Product Type: Adjuvant Emulsions; Pathogen Components; Particulate Adjuvants; Combination Adjuvants; Other Product Types
  • 2) By Route of Application: Human Vaccine Adjuvants; Veterinary Vaccine Adjuvants
  • 3) By Route of Administration: Oral; Intramuscular; Intranasal; Subcutaneous; Intradermal
  • 4) By Disease: Cancer; Infectious Diseases; Other Diseases
  • Companies Mentioned: GlaxoSmithKline Plc.; Novavax Inc.; SPI Pharma Inc.; Agenus Inc.; CSL Limited
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Vaccine adjuvants refer to compounds or components included in vaccines to enhance the body's immune response to antigens that lack immunostimulatory capabilities, thereby creating a more robust immune reaction.

The primary categories of vaccine adjuvants include adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and others, such as saponin-based adjuvants. Adjuvant emulsions are defined as mixtures of two or more typically immiscible liquids. These vaccine adjuvants are administered through various routes, including oral, intramuscular, intranasal, subcutaneous, and intradermal, in both human and veterinary settings. They are employed in the treatment of conditions such as cancer, infectious diseases, and other ailments, including zoonotic diseases.

The vaccine adjuvants market research report is one of a series of new reports from The Business Research Company that provides vaccine adjuvants market statistics, including the vaccine adjuvants industry's global market size, regional shares, competitors with a vaccine adjuvants market share, detailed vaccine adjuvants market segments, market trends, and opportunities, and any further data you may need to thrive in the vaccine adjuvants industry. This vaccine adjuvants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vaccine adjuvants market size has grown strongly in recent years. It will grow from $1.77 billion in 2023 to $1.91 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth observed in the historical period can be ascribed to the rise in vaccine development, the prevalence of infectious diseases, government initiatives, and immunization programs, substantial investments in research and development, as well as the globalization of vaccine distribution.

The vaccine adjuvants market size is expected to see strong growth in the next few years. It will grow to $2.62 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The anticipated growth in the forecast period can be linked to preparedness for pandemics, the diversification of vaccine portfolios, global objectives for immunization, collaborative efforts and partnerships, and an emphasis on therapeutic vaccines. Prominent trends expected in the forecast period encompass progress in adjuvant technologies, a focus on enhancing immunogenicity, the use of combination adjuvants for heightened effectiveness, a demand for safer and well-tolerated adjuvants, as well as the development of personalized vaccines and adjuvants.

The anticipated growth of the vaccine adjuvants market is expected to be driven by the increasing prevalence of infectious diseases. Infectious diseases encompass infections caused by viruses, bacteria, fungi, or parasites. Vaccines play a crucial role in treating various infectious diseases such as hepatitis B (HBV), hepatitis C (HCV), HIV, malaria, syphilis, and brucellosis. As per the 2022 World Health Organization (WHO) report, approximately 10.6 million people globally were infected with tuberculosis in 2021, resulting in 1.6 million deaths, and 1.5 million individuals contracted HIV, with 650,000 losing their lives to it. Hence, the rising prevalence of infectious diseases is expected to be a key driver for the vaccine adjuvants market.

The expected growth of the vaccine adjuvants market is also anticipated to be fueled by the increasing funding for vaccine research activities. Vaccine research activities encompass comprehensive scientific endeavors focused on developing, testing, and enhancing vaccines to prevent infectious diseases. These research activities play a crucial role in identifying, testing, and optimizing potential adjuvant candidates derived from diverse sources, including natural products, synthetic compounds, and even bacteria or viruses. For example, in October 2023, the United States Department of Health and Human Services, a US-based provider of essential human services, announced Project NextGen, involving a $500 million investment to initiate the development of Phase 2b clinical trial plans and cutting-edge technologies for next-generation vaccination and treatment platforms. Consequently, the increasing funding for vaccine research activities is a driving force behind the growth of the vaccine adjuvants market.

The adoption of strategic partnerships is emerging as a significant trend in the vaccine adjuvants market, with numerous companies seeking collaborations to fortify their market positions. For example, in October 2021, Dynavax Technologies, a biotech company based in the US, joined forces with the U.S. Department of Defense to develop a plague vaccine enhanced with Dynavax's CpG 1018 adjuvant. Additionally, in September 2020, Valneva SE, a biotech company based in France, partnered with Dynavax, a US-based biotech company, to manufacture an adjuvant for the COVID-19 vaccine.

Prominent companies operating in the vaccine adjuvants market are concentrating on introducing innovative products, such as plant-based squalene, to gain a competitive advantage. Plant-based squalene, derived from the herbaceous plant amaranth (Amaranthus caudatus), offers a sustainable and cruelty-free alternative to traditional squalene obtained from shark liver oil. For instance, in December 2022, Evonik Industries AG, a specialty chemicals company based in Germany, launched PhytoSquene, a plant-based squalene utilized in adjuvants to enhance vaccine efficacy. This product has applications in adjuvants for parenteral vaccines, with potential expansion into other pharmaceutical and cosmetic uses. PhytoSquene addresses the needs of patients who, due to cultural or religious beliefs, cannot use products derived from animals.

In August 2022, GSK plc, a pharmaceutical and biotechnology company based in the UK, completed the acquisition of Affinivax Inc. for a deal amount of $3.3 billion. This acquisition bolsters GSK's strategy to establish a substantial portfolio of specialized novel drugs and vaccines. It includes a next-generation 24-valent pneumococcal vaccine adjuvant (AFX3772), based on the groundbreaking Multiple Antigen Presenting System (MAPSTM) platform technology, currently in phase II development. Affinivax Inc. is a clinical-stage biopharmaceutical company based in the UK operating in the vaccine adjuvant market.

Major companies operating in the vaccine adjuvants market report are GlaxoSmithKline Plc., Novavax Inc., SPI Pharma Inc., Agenus Inc., CSL Limited, InvivoGen Limited., Brenntag Biosector A/S, Adjuvatis, Merck KGaA, Croda International Plc, Seppic Inc., OZ Biosciences, Avanti Polar Lipids Inc., Astellas Pharma Inc., Virometix AG, MPV Technologies Limited, Adjuvance Technologies Inc., Novartis AG, Vaxine Pty Ltd., SBI Biotech Co. Ltd., Statens Serum Institute, GSK Vaccines, VaxLiant LLC, VaxForm LLC, Serum Institute of India, Dynavax Technologies Corporation, Vaxcyte Inc., VBI Vaccines Inc., Medicago Inc., Aphios Corporation

North America was the largest region in the vaccine adjuvants market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global vaccine adjuvants market report during the forecast period. The regions covered in the vaccine adjuvants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the vaccine adjuvants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The vaccine adjuvants market consists of sales of adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and saponin-based adjuvants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Vaccine Adjuvants Market Characteristics

3. Vaccine Adjuvants Market Trends And Strategies

4. Vaccine Adjuvants Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Vaccine Adjuvants Market Size and Growth

  • 5.1. Global Vaccine Adjuvants Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Vaccine Adjuvants Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Vaccine Adjuvants Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Vaccine Adjuvants Market Segmentation

  • 6.1. Global Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Adjuvant Emulsions
  • Pathogen Components
  • Particulate Adjuvants
  • Combination Adjuvants
  • Other Product Types
  • 6.2. Global Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Human Vaccine Adjuvants
  • Veterinary Vaccine Adjuvants
  • 6.3. Global Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Intramuscular
  • Intranasal
  • Subcutaneous
  • Intradermal
  • 6.4. Global Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Cancer
  • Infectious Diseases
  • Other Diseases

7. Vaccine Adjuvants Market Regional And Country Analysis

  • 7.1. Global Vaccine Adjuvants Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Vaccine Adjuvants Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Vaccine Adjuvants Market

  • 8.1. Asia-Pacific Vaccine Adjuvants Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Vaccine Adjuvants Market

  • 9.1. China Vaccine Adjuvants Market Overview
  • 9.2. China Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Vaccine Adjuvants Market

  • 10.1. India Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Vaccine Adjuvants Market

  • 11.1. Japan Vaccine Adjuvants Market Overview
  • 11.2. Japan Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Vaccine Adjuvants Market

  • 12.1. Australia Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Vaccine Adjuvants Market

  • 13.1. Indonesia Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Vaccine Adjuvants Market

  • 14.1. South Korea Vaccine Adjuvants Market Overview
  • 14.2. South Korea Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Vaccine Adjuvants Market

  • 15.1. Western Europe Vaccine Adjuvants Market Overview
  • 15.2. Western Europe Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Vaccine Adjuvants Market

  • 16.1. UK Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Vaccine Adjuvants Market

  • 17.1. Germany Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Vaccine Adjuvants Market

  • 18.1. France Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Vaccine Adjuvants Market

  • 19.1. Italy Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Vaccine Adjuvants Market

  • 20.1. Spain Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Vaccine Adjuvants Market

  • 21.1. Eastern Europe Vaccine Adjuvants Market Overview
  • 21.2. Eastern Europe Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Vaccine Adjuvants Market

  • 22.1. Russia Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Vaccine Adjuvants Market

  • 23.1. North America Vaccine Adjuvants Market Overview
  • 23.2. North America Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Vaccine Adjuvants Market

  • 24.1. USA Vaccine Adjuvants Market Overview
  • 24.2. USA Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Vaccine Adjuvants Market

  • 25.1. Canada Vaccine Adjuvants Market Overview
  • 25.2. Canada Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Vaccine Adjuvants Market

  • 26.1. South America Vaccine Adjuvants Market Overview
  • 26.2. South America Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Vaccine Adjuvants Market

  • 27.1. Brazil Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Vaccine Adjuvants Market

  • 28.1. Middle East Vaccine Adjuvants Market Overview
  • 28.2. Middle East Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Vaccine Adjuvants Market

  • 29.1. Africa Vaccine Adjuvants Market Overview
  • 29.2. Africa Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Vaccine Adjuvants Market Competitive Landscape And Company Profiles

  • 30.1. Vaccine Adjuvants Market Competitive Landscape
  • 30.2. Vaccine Adjuvants Market Company Profiles
    • 30.2.1. GlaxoSmithKline Plc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novavax Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. SPI Pharma Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Agenus Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. CSL Limited
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Vaccine Adjuvants Market Competitive Benchmarking

32. Global Vaccine Adjuvants Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Vaccine Adjuvants Market

34. Vaccine Adjuvants Market Future Outlook and Potential Analysis

  • 34.1 Vaccine Adjuvants Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Vaccine Adjuvants Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Vaccine Adjuvants Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer